Assenagon Asset Management S.A. Has $386,000 Holdings in Ocular Therapeutix, Inc. $OCUL

Assenagon Asset Management S.A. cut its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 92.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,600 shares of the biopharmaceutical company’s stock after selling 575,214 shares during the period. Assenagon Asset Management S.A.’s holdings in Ocular Therapeutix were worth $386,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Steward Partners Investment Advisory LLC lifted its stake in shares of Ocular Therapeutix by 124.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,242 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Ocular Therapeutix by 1.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock valued at $674,000 after buying an additional 1,314 shares during the last quarter. Trust Co. of Vermont grew its stake in Ocular Therapeutix by 24.3% in the 4th quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,750 shares during the last quarter. Rafferty Asset Management LLC raised its holdings in Ocular Therapeutix by 21.2% in the 2nd quarter. Rafferty Asset Management LLC now owns 13,413 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 2,343 shares during the period. Finally, Rockefeller Capital Management L.P. bought a new position in Ocular Therapeutix in the 4th quarter worth $31,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Price Performance

Shares of Ocular Therapeutix stock opened at $9.64 on Friday. The firm has a market cap of $2.11 billion, a P/E ratio of -6.60 and a beta of 0.88. The firm’s 50-day simple moving average is $9.11 and its 200-day simple moving average is $9.65. Ocular Therapeutix, Inc. has a twelve month low of $6.23 and a twelve month high of $16.44. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81.

Analysts Set New Price Targets

A number of research analysts have weighed in on OCUL shares. Needham & Company LLC reissued a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, May 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and set a $25.00 price objective (up from $21.00) on shares of Ocular Therapeutix in a research report on Thursday, June 18th. Robert W. Baird boosted their price objective on Ocular Therapeutix from $24.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Finally, Chardan Capital increased their target price on Ocular Therapeutix from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Ocular Therapeutix presently has an average rating of “Moderate Buy” and a consensus price target of $25.11.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,156 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total transaction of $173,479.20. Following the completion of the transaction, the insider owned 2,597,170 shares in the company, valued at $21,296,794. This trade represents a 0.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 28,999 shares of company stock worth $237,792 in the last three months. 3.10% of the stock is owned by company insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.